PR
For a better future SCM Lifescience will do its best
SCM Life Science, Completed administration of the first patient in phase 2 clinical trial of "SCM-AGH", a treatment for atopic dermatitis.
News
2022-01-28

SCM Life Science (SCM Life Science, KOSDAQ 298060, CEO Lee Byung-gun), a company specializing in cell therapy, On the 16th, announced that it has completed the first patient administration of phase 2 clinical trials for its atopic dermatitis stem cell treatment "SCM-AGH."

 

SCM Life Science received approval for phase 2 clinical IRB from a total of 11 hospitals, including Seoul National University Hospital, Sinchon Severance Hospital, and Kyunghee University Hospital, on the 9th. IRB is refers to a voting body in a general hospital that approves clinical research by deliberating on the appropriateness, safety, and ethics of research for the safety of participants.

Starting with Inha University Hospital, which completed its first patient administration this time, Scm Life Science plans to conduct phase 2 clinical trials for 72 patients in a total of 11 hospitals.

 

In December last year, Scm Life Science successfully completed phase 1 clinical trials for SCM-AGH. According to the announcement of Scm Life Science, 13 (68%) patients had improved their EASI score by more than 50%, an indicator of the severity of atopic dermatitis in phase 1 clinical trials conducted on 19 patients. In addition, long-term efficacy of SCM-AGH was observed in all patients who completed visits up to 24 weeks of improvement in EASI scores by 50% or more (12 patients, the remaining one less than 24 weeks).

 

SCM-AGH, a stem cell-based treatment, is expected to be of great help to patients suffering from atopic dermatitis if the clinical final stage is successfully completed.

 

The global market size of atopic dermatitis treatments is about 10 trillion, and it is expected to grow to 18 trillion by 2027.

 

Currently commercialized atopic dermatitis treatments are cumbersome to be administered frequently because they are only expensive to treat and temporarily improve symptoms. SCM Life Science plans to prove the effectiveness and safety of stem cell treatments in phase 2 clinical trials and confirm commerciality such as reducing treatment costs.

 

 

 

 

 

LIST